Last reviewed · How we verify
Standard medication for variant angina
Calcium channel blockers relax coronary artery smooth muscle to prevent vasospasm and improve blood flow in variant angina.
Calcium channel blockers relax coronary artery smooth muscle to prevent vasospasm and improve blood flow in variant angina. Used for Variant angina (Prinzmetal's angina), Angina pectoris prevention.
At a glance
| Generic name | Standard medication for variant angina |
|---|---|
| Also known as | Calcium Channel blocker or NG |
| Sponsor | Seoul National University Hospital |
| Drug class | Calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Variant angina (Prinzmetal's angina) is caused by episodic coronary artery vasospasm. Calcium channel blockers inhibit L-type calcium channels in vascular smooth muscle, preventing the influx of calcium ions that triggers vasoconstriction. This reduces the frequency and severity of vasospastic episodes and relieves anginal chest pain.
Approved indications
- Variant angina (Prinzmetal's angina)
- Angina pectoris prevention
Common side effects
- Headache
- Dizziness
- Peripheral edema
- Constipation
- Hypotension
- Bradycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: